Biomednewsbreaks - Nrx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Feedback On Bioequivalence For Ketamine Product March 18, 2026 depression ONLY AVAILABLE IN PAID PLANS. Originally reported by menafn. Read more Source: https://menafn.com/1110873691/Biomednewsbreaks-Nrx-Pharmaceuticals-Inc-NASDAQ-NRXP-Receives-FDA-Feedback-On-Bioequivalence-For-Ketamine-Product
